about
PPARalpha is essential for microparticle-induced differentiation of mouse bone marrow-derived endothelial progenitor cells and angiogenesisIncreased oxidative stress induces apoptosis in human cystic fibrosis cellsIncreased microparticle production and impaired microvascular endothelial function in aldosterone-salt-treated rats: protective effects of polyphenols.Whole mount immunofluorescent staining of the neonatal mouse retina to investigate angiogenesis in vivoEndothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression.Using MRI to predict future adverse cardiac remodelling in a male mouse model of myocardial infarction.Microparticles: targets and tools in cardiovascular disease.Mouse models of hereditary hemorrhagic telangiectasia: recent advances and future challenges.Interaction in endothelium of non-muscular myosin light-chain kinase and the NF-κB pathway is critical to lipopolysaccharide-induced vascular hyporeactivity.Hepatic protein tyrosine phosphatase 1B (PTP1B) deficiency protects against obesity-induced endothelial dysfunction.Cardiosphere-Derived Cells Require Endoglin for Paracrine-Mediated Angiogenesis.Circulating microparticles from patients with obstructive sleep apnea enhance vascular contraction: mandatory role of the endothelium.Circulating microparticles from obstructive sleep apnea syndrome patients induce endothelin-mediated angiogenesis.Soluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasiaDecreased Expression of Vascular Endothelial Growth Factor Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2Length-independent telomere damage drives post-mitotic cardiomyocyte senescenceDisruption of embryonic ROCK signaling reproduces the sarcomeric phenotype of hypertrophic cardiomyopathy.Microvesicles: intercellular vectors of biological messagesMicroparticle release in remote ischemic conditioning mechanism
P50
Q33682146-3E820880-B9F4-48F7-BC20-84ABA456AD24Q34024098-BEFAC30A-267B-43DC-AC7A-16BC803796DCQ34341545-1E8C3B0D-2732-442E-9C59-CA4A374A8D49Q34871044-57EC17AC-D779-48EA-800D-C91F1889CFA7Q35181476-C03DC0E3-891B-4942-B713-50BCDF3078BAQ37417454-A0F8277E-A8B3-4570-BE37-D961A98EB0CBQ37906852-9A044AE5-FC64-46CF-A454-2FB56E2C9457Q38367817-77E93AA8-80E1-4859-9A10-3ECE344164DAQ41095597-290C83B9-92F7-4BB5-AA7A-A1BDEE9FFB44Q41753143-0A27A524-FBDB-4563-8963-78CFFE89752DQ42278077-27912148-3427-4362-86DD-351BC9DB06DCQ47323845-4F9AE67D-6181-4D48-A777-4C52645D50DDQ48141617-CFCA6791-60C9-4097-9F59-80FC175111B8Q58703191-ba2079c8-4c20-fe4e-3792-ae08a8fb84a8Q63915610-A4A0DF5D-79F8-48E0-90F0-420967F5B7C3Q64233922-EEB1B1BB-7680-4C67-9E01-EE1081E21CC2Q64975647-2BF69CF4-8962-4641-AE8B-1F3722B05CF8Q84028267-3D8B15A7-A8D3-4C57-9BC4-4D4FAA66D6AEQ84780071-8EA77690-A8CA-4811-8610-62B1FE021BCD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Simon Tual-Chalot
@ast
Simon Tual-Chalot
@en
Simon Tual-Chalot
@es
Simon Tual-Chalot
@nl
type
label
Simon Tual-Chalot
@ast
Simon Tual-Chalot
@en
Simon Tual-Chalot
@es
Simon Tual-Chalot
@nl
prefLabel
Simon Tual-Chalot
@ast
Simon Tual-Chalot
@en
Simon Tual-Chalot
@es
Simon Tual-Chalot
@nl
P106
P31
P496
0000-0002-9307-7175